Patents by Inventor Julian Alexander Barden

Julian Alexander Barden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20220315652
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: March 10, 2021
    Publication date: October 6, 2022
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Cytotoxic Particles for Targeting P2X7 Receptor
    Publication number: 20220249692
    Abstract: The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 receptors on a cancer cell.
    Type: Application
    Filed: January 13, 2022
    Publication date: August 11, 2022
    Inventors: Xiaojuan GONG, Minoo J MOGHADDAM, Julian Alexander BARDEN
  • Cytotoxic particles for targeting P2X7 receptor
    Patent number: 11260131
    Abstract: The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 preceptorson a cancer cell.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 1, 2022
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Xiaojuan Gong, Minoo J Moghaddam, Julian Alexander Barden
  • Anti P2Xreceptor antibodies and fragments thereof
    Patent number: 10988532
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: April 27, 2021
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Methods of treating cancer with a P2X7 peptide
    Patent number: 10597451
    Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 24, 2020
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR
    Publication number: 20200071419
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 5, 2020
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Combination therapy utilizing P2X7 peptides
    Patent number: 10543262
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimising the progression of cancer in said individuals.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: January 28, 2020
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor
    Patent number: 10450380
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: October 22, 2019
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Combination Therapy Utilizing P2X7 Peptides
    Publication number: 20190224290
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimising the progression of cancer in said individuals.
    Type: Application
    Filed: February 5, 2019
    Publication date: July 25, 2019
    Applicant: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • CYTOTOXIC PARTICLES
    Publication number: 20190201545
    Abstract: The invention relates to cytotoxic particles for cancer therapy including a core and a plurality of variable domains arranged on the core for binding to P2X7 receptorson a cancer cell.
    Type: Application
    Filed: August 18, 2017
    Publication date: July 4, 2019
    Inventors: Xiaojuan GONG, Minoo J MOGHADDAM, Julian Alexander BARDEN
  • Combination therapy utilizing P2X7 peptides
    Patent number: 10245308
    Abstract: The invention relates to producing humoral response to P2X7 receptors in individuals having cancer, and to minimizing the progression of cancer in said individuals.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 2, 2019
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Anti-P2Xpeptides and epitopes
    Patent number: 10238716
    Abstract: The invention relates to the identification of a novel epitope on non-function P2X7 receptors which are implicated in cancer. The epitope includes a region from two adjacent monomers within the three subunit receptor. Antibodies which bind to the epitope and peptides for generating the antibodies are described. The antibodies and peptides are useful in the diagnosis and treatment of cancer.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: March 26, 2019
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Method for minimising progression of cancer in companion animals
    Patent number: 10232025
    Abstract: The invention relates to minimizing the progression of cancer in a companion animal using P2X7 immunotherapy.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 19, 2019
    Assignee: BIOSCEPTRE (AUSI) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20190040129
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: July 11, 2018
    Publication date: February 7, 2019
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • NOVEL P2X7 EPITOPES
    Publication number: 20180265580
    Abstract: The invention relates to purinergic (P2X) receptors, more specifically to P2X7 receptors, the generation of antibodies and the use of antibodies and immunogens that are capable of selectively binding to a non ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, for the detection and treatment of disease conditions, especially cancer.
    Type: Application
    Filed: March 2, 2018
    Publication date: September 20, 2018
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Anti P2X7 receptor antibodies and fragments thereof
    Patent number: 10053508
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: August 21, 2018
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • Methods of treating cancer with antibodies that bind P2X7 receptors
    Patent number: 9944701
    Abstract: The invention relates to purinergic (P2X) receptors, to generation of antibodies and to use of antibodies and immunogens for detection and treatment of a disease or condition, especially cancer.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: April 17, 2018
    Assignee: BIOSCEPTRE (AUST) PTY LTD
    Inventors: Julian Alexander Barden, Angus Gidley-Baird
  • Pain Treatment
    Publication number: 20180037650
    Abstract: A method of managing pain in an individual including the following steps: providing an individual in need of pain management; administering an anti-P2X7 receptor antibody to the individual; thereby managing pain in the individual.
    Type: Application
    Filed: April 1, 2016
    Publication date: February 8, 2018
    Inventor: Julian Alexander Barden
  • ANTI P2X7 RECEPTOR ANTIBODIES AND FRAGMENTS THEREOF
    Publication number: 20170327576
    Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4
    Type: Application
    Filed: May 18, 2017
    Publication date: November 16, 2017
    Inventors: Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
  • ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR
    Publication number: 20170327592
    Abstract: The present invention provides antibodies that specifically bind to P2X7 receptors and distinguish between function and non-functional P2X7 receptors, pharmaceutical compositions and kits containing the antibodies, and methods of using the antibodies for the detection, diagnosis and treatment of disease conditions.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 16, 2017
    Inventors: Julian Alexander Barden, Angus Gidley-Baird